India Needs Proper Biosupplier Ecosystem
Bio Spectrum
|September 2017
With economic growth and addition of biotechnology to its portfolio, India is rapidly becoming a global player in the life sciences and healthcare space. Educating and achieving scientific excellence demands a really high level of R&D. Now that the government is investing more resources in research and medical facilities and infrastructure, from educational institutes to hospitals, use of lab equipment, reagents or medical devices are growing rapidly. This will drive the growth of biosupplier market in the country.
-
India’s life sciences and healthcare industry has changed dramatically in the last decade, moving from import dependency to self-sufficiency, and this has created demand for innovative new technologies. Fueling this growth has been increasing demand from biosuppliers who are challenged to provide innovative and productive solutions that not only support India, but also enable them to compete globally.
Other notable trends in the past few years have been an intensive focus on R&D within pharmaceutical, biotech and healthcare as well as demand from the government sector (mainly R&D institutes). “This has led to new investments in high-end analytical instruments and consumables to support everything from food safety and drug discovery to precision medicine,” said Amit Chopra, Managing Director – India and Middle East, Thermo Fisher Scientific while commenting on trends in biosuppliers market with respect to life sciences and healthcare industry in India.
Biosuppliers are witnessing unprecedented growth opportunities in India due to high growth in the Biopharma and healthcare market. Pharmaceuticals, life sciences and healthcare companies are experiencing a wave of competing challenges currently.
Sharing her views on trends in biosuppliers Dr Deepanwita Chattopadhyay, Chairman & CEO, IKP Knowledge Park said “We have started producing the reagents in the country but a large amount is still being imported. I am seeing people getting into the reagents and suppliers business. It’s also about acceptance. The market depends also on buyers and not just sellers. If academic institutions and companies buy the Indian product and if they can establish the confidence then only their share in the market will increase. I think this process has already been started and slowly picking up.”
This story is from the September 2017 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
India's Strategic Shift Towards High-Quality, Low-Cost MedTech
India's healthcare infrastructure continues to face significant strain from the rising prevalence of non-communicable diseases (NCDs), contributing around 66 per cent of the mortalities in the country, underscoring the need for scalable continuous monitoring, early diagnosis, and therapeutic devices. Yet, advanced imaging systems, analysers, surgical tools, or robotic devices remain very expensive due to import reliance, high logistics costs, and maintenance/ service contracts. Segments showing strongest traction today are diagnostics (point-of-care devices, rapid tests, compact imaging devices), remote monitoring/wearable devices, and therapeutic devices such as surgical robotic systems, renal care systems, and wound care devices.
4 mins
December 2025
Bio Spectrum
How India's Diabetes Crisis is Driving Med Devices Market
A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.
9 mins
December 2025
Bio Spectrum
Thermo Fisher Scientific invests Rs 160 Cr+ to expand Bengaluru R&D facility
Thermo Fisher Scientific's expanded Research and Development (R&D) Centre of Excellence was inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM).
1 min
December 2025
Bio Spectrum
Motorica strengthens India presence with appointment of Kavinder Beniwal as COO
Motorica, a Delhi-based medtech company specialising in assistive technologies and medical cybernetics, has announced the appointment of Kavinder Beniwal as Chief Operational Officer (COO) of Motorica India.
1 min
December 2025
Bio Spectrum
Cabinet approves major expansion of PG and UG medical education capacity
Union Cabinet chaired by the Prime Minister Narendra Modi has approved the Phase-Ill of the Centrally Sponsored Scheme (CSS) for strengthening and upgradation of existing State Government/ Central Government Medical Colleges/Standalone PG Institutes/ Government Hospitals for increasing 5,000 PG seats and extension of the CSS for upgradation of existing government medical colleges for increasing 5,023 MBBS seats with an enhanced cost ceiling of Rs 1.5 crore per seat.
1 min
December 2025
Bio Spectrum
Dr Sharvil Patel steps in as Indian Pharmaceutical Alliance President
The Indian Pharmaceutical Alliance (IPA) has announced a leadership transition, with Dr Sharvil Patel, Managing Director of Zydus Lifesciences and former Vice President of IPA, assuming the role of President.
1 min
December 2025
Bio Spectrum
PAG-led Sekhmet Pharmaventures announces appointment of Mukesh Agarwal as CFO
Hyderabad-based Sekhmet Pharmaventures, a fast-emerging global API/CDMO player led by leading Asia-focused investment firm PAG, has announced the appointment of Mukesh Agarwal as its new Chief Financial Officer (CFO).
1 min
December 2025
Bio Spectrum
Monash University Malaysia and Tata Chemicals forge healthcare researchfocused partnership
The importance of gastrointestinal health is a key focus for researchers and innovators, as highlighted by the partnership between Monash University Malaysia and Tata Chemicals Limited.
1 min
December 2025
Bio Spectrum
"India has the talent and ambition to lead globally in advanced therapies, biologics, and oncology"
Thermo Fisher Scientific has recently announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. Central to this expansion strategy are two major facilities in Genome Valley, Hyderabad, i.e. Bioprocess Design Center (BDC), and Customer Experience Center (CEC). In addition, the company has invested more than Rs 160 crore this year to expand its R&D facility in Bengaluru. For further understanding on these new developments, BioSpectrum spoke in detail to Srinath Venkatesh, Managing Director, India & South Asia, Thermo Fisher Scientific. Edited excerpts;
4 mins
December 2025
Bio Spectrum
"AI is a transformative enabler that's reshaping how science is conducted in labs"
2025 witnessed multiple new initiatives taken by Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, for the Indian market. These initiatives included establishment of an India Solutions Center in Manesar; and a Biopharma Experience Center in Hyderabad. 2025 also saw Nandakumar Kalathil stepping in as the new Country General Manager for Agilent India. With over 25 years of experience in the analytical industry, Nanda brings extensive expertise in leadership, team management, and customer relations. To find out more about the company's growth plans in 2026 in India, BioSpectrum interacted with Nandakumar Kalathil, Country General Manager for Agilent India in detail. Edited excerpts:
4 mins
December 2025
Translate
Change font size

